RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) will report its third-quarter 2026 financial results after U.S. markets close Wednesday, November 4, providing investors with an update as the Radnor-based biopharmaceutical company advances its experimental hypertension treatment, lorundrostat.
The company has scheduled a conference call and webcast for 4:30 p.m. Eastern Time that day to discuss results for the quarter ended September 30.
Investors can access the call domestically at 1-877-704-4453 or internationally at 1-201-389-0920, using conference ID 13762560.
The live webcast will be available at https://viavid.webcasts.com/starthere.jsp?ei=1775225&tp_key=0c9d396460 and through the News & Events page of Mineralys’ investor relations website.
Mineralys is developing lorundrostat, an investigational oral aldosterone synthase inhibitor designed to reduce the production of aldosterone, a hormone involved in blood pressure regulation.
The company’s research focuses on uncontrolled and resistant hypertension and related conditions, including chronic kidney disease and obstructive sleep apnea.
Mineralys, which was founded by Catalys Pacific, is headquartered in Radnor, Pennsylvania. Additional corporate information is available at https://mineralystx.com.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.